Nanomix, a Emeryville, Calif.-based developer of point-of-care diagnostic tests, raised approximately $12m in financing.
A strategic corporate partner as well as unnamed existing investors participated in the round.
The company intends to use the funds for development, registration of clinical trials, and commercial launch of its mobile diagnostic platform and initial assays.
Led by David Ludvigson, President and CEO, Nanomix is a nanotechnology company focused on development of innovative Point of Care diagnostic tests to enable earlier and more accurate testing in hospital and pre-hospital settings. Its mobile diagnostic platform performs multiple in-vitro diagnostic assays simultaneously from a single whole-blood sample.
FinSMEs
31/01/2014